Rachel Haurwitz, Caribou CEO (Kimberly White/Getty Images for TechCrunch)
March 3, 2021 08:00 AM ESTUpdated 09:16 AM
Financing

A Jen­nifer Doud­na-launched up­start nabs $115M for off-the-shelf CAR-Ts

Nicole DeFeudis

Editor

There is no short­age of biotechs pur­su­ing off-the-shelf CAR-Ts, a so-called Holy Grail in on­col­o­gy R&D. Now, less than a month af­ter team­ing up with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times